Shinji Asada

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Patient characteristics associated with the need for high doses of tenapanor hydrochloride in dialysis patients with hyperphosphatemia: A pooled analysis of three clinical trials.

Patient characteristics associated with the need for high doses of tenapanor hydrochloride in dialysis patients with hyperphosphatemia: A pooled analysis of three clinical trials.

Journal: PloS one
Published: March 12, 2026

Tenapanor reduces phosphate binder pill burden among hemodialysis patients in a post hoc phase 3 analysis.

Tenapanor reduces phosphate binder pill burden among hemodialysis patients in a post hoc phase 3 analysis.

Journal: Scientific reports
Published: January 28, 2026

Evidence-practice gaps in chronic kidney disease management among patients taking antidiabetic or antihypertensive medications: a nationwide analysis of Japanese primary care electronic health records.

Evidence-practice gaps in chronic kidney disease management among patients taking antidiabetic or antihypertensive medications: a nationwide analysis of Japanese primary care electronic health records.

Journal: Clinical and experimental nephrology
Published: December 24, 2025

Anemia prevalence and treatment patterns in chronic kidney disease: a nationwide observational study using a Japanese primary care database (2018-2023).

Anemia prevalence and treatment patterns in chronic kidney disease: a nationwide observational study using a Japanese primary care database (2018-2023).

Journal: Clinical and experimental nephrology
Published: September 11, 2025

Estimating the impact of pill burden on health utilities in hemodialysis therapy.

Estimating the impact of pill burden on health utilities in hemodialysis therapy.

Journal: Scientific reports
Published: June 12, 2025

Adherence to istradefylline in patients with Parkinson's disease: A group-based trajectory analysis.

Adherence to istradefylline in patients with Parkinson's disease: A group-based trajectory analysis.

Journal: Journal of the neurological sciences
Published: January 25, 2024

Real-world evidence on levodopa dose escalation in patients with Parkinson's disease treated with istradefylline.

Real-world evidence on levodopa dose escalation in patients with Parkinson's disease treated with istradefylline.

Journal: PloS one
Published: May 31, 2022

Corrigendum to "Efficacy of evocalcet in previously cinacalcet-treated secondary hyperparathyroidism patients," [Kidney Int. Rep. 2021; https://doi.org/10.1016/j.ekir.2021.08.020].

Corrigendum to "Efficacy of evocalcet in previously cinacalcet-treated secondary hyperparathyroidism patients," [Kidney Int. Rep. 2021; https://doi.org/10.1016/j.ekir.2021.08.020].

Journal: Kidney international reports
Published: November 26, 2021

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients.

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients.

Journal: Kidney international reports
Published: April 27, 2021

Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism.

Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism.

Journal: PloS one
Published: April 20, 2021

Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism.

Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism.

Journal: PloS one
Published: March 05, 2021

Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism.

Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism.

Journal: BMC nephrology
Published: February 25, 2020
Showing 1-12 of 18

Last Updated: 09/26/2026